Teratogenicity of triamcinolone acetonide in rats

J. M. Rowland, Andrew G Hendrickx

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The objective of this investigation was to study the teratogenic effects of triamcinolone acetonide (TAC) in the rat. Pregnant females were injected intramuscularly once each day for three consecutive days (days 9–11, 12–14, or 15–17 of gestation) either with vehicle alone or with 0.125, 0.25, or 0.5 mg/kg TAC. All animals were euthanized on day 20 of gestation, and the fetuses were fixed for razor blade sectioning and skeletal examination. No maternal lethality was elicited in any of the treatment groups. There were decreases in fetal viability in the two higher dose groups treated on days 12–14 and the group treated with 0.5 mg/kg on days 15–17. These same three treatment groups showed significant increases in the percentage of malformed fetuses. The most prevalent malformation was cleft palate, with both complete and partial clefts being detected. Umbilical hernias and undescended testes were also found to be significantlymore frequent in the high‐dose group treated on days 12–14. A reduced degree of ossification was found in all TAC‐treated groups, but no specific skeletal malformations were detected. Fetal weight was significantly reduced in all TAC‐treated groups. The results demonstrate that (1) TAC affects a variety of developmental processes resulting in resorption, cleft palate, umbilical hernias, undescended testes, reduced ossification, and fetal growth retardation, (2) these teratogenic effects are elicited at doses causing no maternal lethality, and (3) fetal growth retardation can be produced at doses below those required to produce malformations and during periods of gestation where no malformations are produced, supporting the use of this parameter as a sensitive indicator of embryotoxicity.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalTeratology
Volume27
Issue number1
DOIs
StatePublished - 1983

Fingerprint

Triamcinolone Acetonide
Rats
Umbilical Hernia
Cryptorchidism
Fetal Growth Retardation
Cleft Palate
Osteogenesis
Pregnancy
Fetus
Fetal Viability
Mothers
Fetal Weight
Animals

ASJC Scopus subject areas

  • Embryology
  • Toxicology
  • Developmental Biology
  • Health, Toxicology and Mutagenesis

Cite this

Teratogenicity of triamcinolone acetonide in rats. / Rowland, J. M.; Hendrickx, Andrew G.

In: Teratology, Vol. 27, No. 1, 1983, p. 13-18.

Research output: Contribution to journalArticle

Rowland, JM & Hendrickx, AG 1983, 'Teratogenicity of triamcinolone acetonide in rats', Teratology, vol. 27, no. 1, pp. 13-18. https://doi.org/10.1002/tera.1420270104
Rowland, J. M. ; Hendrickx, Andrew G. / Teratogenicity of triamcinolone acetonide in rats. In: Teratology. 1983 ; Vol. 27, No. 1. pp. 13-18.
@article{125cc4ac55fa4ca3b0f369d7be88341e,
title = "Teratogenicity of triamcinolone acetonide in rats",
abstract = "The objective of this investigation was to study the teratogenic effects of triamcinolone acetonide (TAC) in the rat. Pregnant females were injected intramuscularly once each day for three consecutive days (days 9–11, 12–14, or 15–17 of gestation) either with vehicle alone or with 0.125, 0.25, or 0.5 mg/kg TAC. All animals were euthanized on day 20 of gestation, and the fetuses were fixed for razor blade sectioning and skeletal examination. No maternal lethality was elicited in any of the treatment groups. There were decreases in fetal viability in the two higher dose groups treated on days 12–14 and the group treated with 0.5 mg/kg on days 15–17. These same three treatment groups showed significant increases in the percentage of malformed fetuses. The most prevalent malformation was cleft palate, with both complete and partial clefts being detected. Umbilical hernias and undescended testes were also found to be significantlymore frequent in the high‐dose group treated on days 12–14. A reduced degree of ossification was found in all TAC‐treated groups, but no specific skeletal malformations were detected. Fetal weight was significantly reduced in all TAC‐treated groups. The results demonstrate that (1) TAC affects a variety of developmental processes resulting in resorption, cleft palate, umbilical hernias, undescended testes, reduced ossification, and fetal growth retardation, (2) these teratogenic effects are elicited at doses causing no maternal lethality, and (3) fetal growth retardation can be produced at doses below those required to produce malformations and during periods of gestation where no malformations are produced, supporting the use of this parameter as a sensitive indicator of embryotoxicity.",
author = "Rowland, {J. M.} and Hendrickx, {Andrew G}",
year = "1983",
doi = "10.1002/tera.1420270104",
language = "English (US)",
volume = "27",
pages = "13--18",
journal = "Teratology",
issn = "1542-0752",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Teratogenicity of triamcinolone acetonide in rats

AU - Rowland, J. M.

AU - Hendrickx, Andrew G

PY - 1983

Y1 - 1983

N2 - The objective of this investigation was to study the teratogenic effects of triamcinolone acetonide (TAC) in the rat. Pregnant females were injected intramuscularly once each day for three consecutive days (days 9–11, 12–14, or 15–17 of gestation) either with vehicle alone or with 0.125, 0.25, or 0.5 mg/kg TAC. All animals were euthanized on day 20 of gestation, and the fetuses were fixed for razor blade sectioning and skeletal examination. No maternal lethality was elicited in any of the treatment groups. There were decreases in fetal viability in the two higher dose groups treated on days 12–14 and the group treated with 0.5 mg/kg on days 15–17. These same three treatment groups showed significant increases in the percentage of malformed fetuses. The most prevalent malformation was cleft palate, with both complete and partial clefts being detected. Umbilical hernias and undescended testes were also found to be significantlymore frequent in the high‐dose group treated on days 12–14. A reduced degree of ossification was found in all TAC‐treated groups, but no specific skeletal malformations were detected. Fetal weight was significantly reduced in all TAC‐treated groups. The results demonstrate that (1) TAC affects a variety of developmental processes resulting in resorption, cleft palate, umbilical hernias, undescended testes, reduced ossification, and fetal growth retardation, (2) these teratogenic effects are elicited at doses causing no maternal lethality, and (3) fetal growth retardation can be produced at doses below those required to produce malformations and during periods of gestation where no malformations are produced, supporting the use of this parameter as a sensitive indicator of embryotoxicity.

AB - The objective of this investigation was to study the teratogenic effects of triamcinolone acetonide (TAC) in the rat. Pregnant females were injected intramuscularly once each day for three consecutive days (days 9–11, 12–14, or 15–17 of gestation) either with vehicle alone or with 0.125, 0.25, or 0.5 mg/kg TAC. All animals were euthanized on day 20 of gestation, and the fetuses were fixed for razor blade sectioning and skeletal examination. No maternal lethality was elicited in any of the treatment groups. There were decreases in fetal viability in the two higher dose groups treated on days 12–14 and the group treated with 0.5 mg/kg on days 15–17. These same three treatment groups showed significant increases in the percentage of malformed fetuses. The most prevalent malformation was cleft palate, with both complete and partial clefts being detected. Umbilical hernias and undescended testes were also found to be significantlymore frequent in the high‐dose group treated on days 12–14. A reduced degree of ossification was found in all TAC‐treated groups, but no specific skeletal malformations were detected. Fetal weight was significantly reduced in all TAC‐treated groups. The results demonstrate that (1) TAC affects a variety of developmental processes resulting in resorption, cleft palate, umbilical hernias, undescended testes, reduced ossification, and fetal growth retardation, (2) these teratogenic effects are elicited at doses causing no maternal lethality, and (3) fetal growth retardation can be produced at doses below those required to produce malformations and during periods of gestation where no malformations are produced, supporting the use of this parameter as a sensitive indicator of embryotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0020658313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020658313&partnerID=8YFLogxK

U2 - 10.1002/tera.1420270104

DO - 10.1002/tera.1420270104

M3 - Article

C2 - 6845214

AN - SCOPUS:0020658313

VL - 27

SP - 13

EP - 18

JO - Teratology

JF - Teratology

SN - 1542-0752

IS - 1

ER -